Blood Podcast Targeting mutant calreticulin in MPNs; focusing on bleeding risk in patients with cancer; revisiting diagnostic guidelines for familial HLH
7 snips
Nov 28, 2024 Discover the cutting-edge approach of targeting mutant calreticulin in myeloproliferative neoplasms with the monoclonal antibody INCA033989. Delve into the alarming findings from the CAT-BLED study, revealing the significant bleeding risks cancer patients face during systemic therapy. Lastly, gain insights into updated diagnostic guidelines for familial hemophagocytic lymphohistiocytosis, featuring improved clinical criteria and recommendations for cellular and genetic assays.
AI Snips
Chapters
Transcript
Episode notes
Targeting Mutant Calreticulin
- A monoclonal antibody, INCA033989, selectively targets mutant calreticulin in myeloproliferative neoplasms (MPNs).
- This is a potential breakthrough for targeted therapy, addressing an unmet need for mutant CALR-specific treatments.
Bleeding Risk in Cancer Patients
- Cancer patients have a high risk of bleeding, regardless of anticoagulation therapy.
- Clinically relevant bleeding events are associated with poor prognosis and increased all-cause mortality.
Revised HLH Diagnostic Guidelines
- Researchers validated and improved existing diagnostic criteria for familial hemophagocytic lymphohistiocytosis (HLH).
- A seven-criteria clinical model, excluding NK cell activity, offers a reliable and easy-to-perform diagnostic tool.